ASH1L-AS1 and hepatocellular carcinoma: These effects were reversed by ERK1/2 inhibition or ASH1L-AS1 knockdown, highlighting APPLE as a key effector of MAPK-driven oncogenesis in HCC (Figs. 4, 5 and 6).